<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02178488</url>
  </required_header>
  <id_info>
    <org_study_id>D-STAPH-EXT-01</org_study_id>
    <nct_id>NCT02178488</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Vitamin D Supplementation to Meticillin Resistant Staphylococcus Aureus (MRSA) Carriers</brief_title>
  <acronym>D-STAPH</acronym>
  <official_title>Vitamin D Supplementation to Persistent Carriers of MRSA - A Double Blind, Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Bergman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to treat persistent MRSA carriers with vitamin D supplementation
      during a 12 month to see if the number of MRSA positive patients can be reduced.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRSA</measure>
    <time_frame>Baseline, 3, 6, 9 and 12 months</time_frame>
    <description>The primary endpoint is the decline of MRSA-positive patients during a 12-month period in the treatment groups (vitamin D/Placebo) based on 5 measurements with 3 months interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vitamin D levels in serum</measure>
    <time_frame>baseline, 3, 6, 9, 12, 18 and 24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Patterns of DNA methylation in immune cells</measure>
    <time_frame>baseline, 3,6, 9, 12, 18 and 24 months</time_frame>
    <description>Total DNA from whole blood will be isolated and analysed for methylation patterns using the bisulphite exchange method. Focus will be on methylation in genes related to vitamin D metabolism and immunity, including cytochrome p450 number 24 (CYP24), cytochrome p450 number 27 (CYP27) and cathelicidin antimicrobial peptide (CAMP) genes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in microflora in the intestinal and nasal tracts</measure>
    <time_frame>Baseline, 9, 12 and 24 month</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Methicillin Resistant Staphylococcus Aureus</condition>
  <condition>Vitamin D3 Deficiency</condition>
  <arm_group>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 patients with MRSA resistent Cholecalciferol 4000 international units (IU)/day for 12 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugarpill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>150 patients with MRSA resistent Placebo daily 12 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Cholecalciferol 4000 IU/day for 12 months</description>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <other_name>Vigantol Oil (Germany) or Detremin (Sweden)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (mimic of cholecalciferol) in the same amount and same time frame as Cholecalciferol for 12 months</description>
    <arm_group_label>Sugarpill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Persistent MRSA-carriers as defined as 2 MRSA-positive bacterial cultures from at
             least one location, at least 3 months apart and during 3 years prior to inclusion.

          2. Men and women aged ≥18-75

          3. Signed 'informed consent'

          4. Negative pregnancy test (U-hcg) and have to accept the use of adequate anti-conceptive
             method (contraceptives, hormone/copper-spiral).

        Exclusion Criteria:

          1. Should not be on vitamin D supplementation at least 6 months prior to inclusion.

          2. Serum level of 25-hydroxy vitamin D3 &gt;75 nmol/L

          3. Ongoing and continuous antibiotic treatment. The patient should be off antibiotics at
             least 30 days prior to inclusion

          4. Known sarcoidosis

          5. Primary or secondary hyperparathyroidism

          6. Kidney failure as defined as a normal age-adjusted creatinin.

          7. Long term systemic treatment with corticosteroids or other immunosuppressive
             medication

          8. Taking thiazides

          9. Hypercalcaemia (verified by a laboratory result younger than 2 month)

         10. Ongoing malignancy disorder

         11. If plans to leave the Stockholm county within 12 months of inclusion

         12. History of kidney stones

         13. Pregnancy (ongoing or planned)

         14. Breastfeeding women

         15. Taking part of another clinical study involving drugs

         16. Hypersensitivity to cholecalciferol and/or any of the excipients

         17. Other criteria that could jeopardize the study or its intention as judged by the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gudrun Lind, M.D PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital, Solna. Department of Infectious Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Bergman, M.D PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital Huddinge, Department of Infectious Diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <state>Huddinge</state>
        <zip>SE_ 141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <state>Solna</state>
        <zip>SE- 171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://bmjopen.bmj.com/content/2/6/e001663.full.pdf+html</url>
    <description>A report on a previous study where vitamin D/Placebo was given to patients with frequent respiratory tract infections.</description>
  </link>
  <reference>
    <citation>Bergman P, Norlin AC, Hansen S, Rekha RS, Agerberth B, Björkhem-Bergman L, Ekström L, Lindh JD, Andersson J. Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study. BMJ Open. 2012 Dec 13;2(6). pii: e001663. doi: 10.1136/bmjopen-2012-001663. Print 2012.</citation>
    <PMID>23242238</PMID>
  </reference>
  <reference>
    <citation>Matheson EM, Mainous AG 3rd, Hueston WJ, Diaz VA, Everett CJ. Vitamin D and methicillin-resistant Staphylococcus aureus nasal carriage. Scand J Infect Dis. 2010 Jul;42(6-7):455-60. doi: 10.3109/00365541003602049.</citation>
    <PMID>20210515</PMID>
  </reference>
  <reference>
    <citation>Hewison M. Antibacterial effects of vitamin D. Nat Rev Endocrinol. 2011 Jun;7(6):337-45. doi: 10.1038/nrendo.2010.226. Epub 2011 Jan 25. Review. Erratum in: Nat Rev Endocrinol. 2011 Aug;7(8):436.</citation>
    <PMID>21263449</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2014</study_first_posted>
  <last_update_submitted>January 21, 2018</last_update_submitted>
  <last_update_submitted_qc>January 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Peter Bergman</investigator_full_name>
    <investigator_title>Associated professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

